Sanofi

Q3 2025 13F-HR Holdings

Location
Paris, I0
Holdings as of
9/30/2025
Date filed
11/4/2025
Form type
13F-HR
Num holdings
9
Total value ($000)
$260,361
Net value change ($000)
+84,618 (48.1%)
New positions
1
Sold out positions
2
Turnover %
8.6%
Sector allocation + QoQ delta (equities-only)
Prev filing: 7/29/2025 Next filing: 2/11/2026 SEC filing

Snapshot: Change Analysis

Compared to Q2 2025
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
INBX 22,475 136.0%
MGTX 20,858 26.2%
IMRX 18,960 NEW
NVAX 16,307 37.6%
ANAB 6,920 37.9%
OMDA 2,000 20.8%
LAVA Therapeutics NV 460 18.2%
QTTB 119 32.7%
Top Reduces (Value $000, Stocks/ETFs)
INOZYME PHARMA INC -1,773 -100.0%
IGM Biosciences, Inc. -1,612 -100.0%
ELDN -98 -4.4%
Instrument mix + QoQ Δ (ex-options)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type